血清TK1联合CA19-9在胰腺癌和胰腺炎鉴别诊断中的应用价值研究-现代医学

血清TK1联合CA19-9在胰腺癌和胰腺炎鉴别诊断中的应用价值研究

单位：恩施土家族苗族自治州中心医院急诊科, 湖北恩施 445000

分类号：R576

出版年·卷·期（页码）：2017·36·第四期（563-566）

摘要：

目的：探讨联合检测胰腺癌、胰腺炎患者的血清胸苷激酶（TK1）、糖类抗原19-9（CA19-9）鉴别诊断胰腺癌、胰腺炎的临床价值。方法：选取2015年6月—2016年6月在本院接受诊治的87例胰腺癌患者、急性胰腺炎患者60例进行分析，检测两组患者的血清TK-1、CA19-9水平，计算二者联合检测时鉴别诊断胰腺癌、胰腺炎的临床价值。结果：胰腺癌组患者的血清TK-1、CA19-9水平均高于胰腺炎组，差异具有统计学意义（P < 0.05）；胰腺癌组患者的血清ALT、AST、ALP水平均低于胰腺炎组，差异具有统计学意义（P < 0.05）；血清TK-1+CA19-9鉴别诊断胰腺癌、胰腺炎的灵敏度为90.80%、特异度95.00%、漏诊率9.20%、误诊率5.00%，ROC曲线下面积AUC值为0.926。结论：联合检测胰腺癌、胰腺炎患者的血清TK1、CA19-9鉴别诊断胰腺癌、胰腺炎具有较高的临床价值。

Objective: To investigate the clinical value of combined detection of serum thymidine kinase (TK1) and carbohydrate antigen 19-9 (CA19-9) in the differential diagnosis of pancreatic cancer and pancreatitis in patients with pancreatic cancer and pancreatitis. Methods: Eighty seven cases of patients with pancreatic cancer and 60 cases of acute pancreatitis patients from June 2015 to June 2016 were selected and analyzed in our hospital. Serum TK-1, CA19-9 level were detected,and the combined detecting value of differential diagnosis of pancreatic cancer and pancreatitis was evaluated. Results: Serum TK-1, CA19-9 in pancreatic cancer patients was higher than the average in pancreatitis group, the difference had statistical significance (P <0.05); serum ALT, AST and ALP levels in pancreatic cancer patients were lower than those in the acute pancreatitis group, the difference being statistical significant (P<0.05); the sensitivity of serum TK-1+CA19-9 in differential diagnosis of pancreatic cancer and pancreatitis was 90.80%, specificity was 95.00%, misdiagnosis rate 9.20%, misdiagnosis rate 5.00%, area under the ROC curve AUC 0.926.Conclusion: Combined detection of serum TK1 and CA19-9 in patients with pancreatic cancer and pancreatitis has high clinical value in the differential diagnosis of pancreatic cancer and pancreatitis.

参考文献：

[1] 李文新,沙如拉,包佳琪,等.胰腺癌患者术前PET/CT对术后复发及预后预测价值分析[J].中华肿瘤防治杂志,2015,22(14):1138-1142.
[2] 金克敏,王立军,刘伟,等.转移淋巴结数目对胰腺癌患者预后的意义[J].中华普通外科杂志,2016,31(1):17-22.
[3] AL-JANABI A,TAWFEEQ E F.Interfering effect of black tea consumption on diagnosis of pancreatic cancer by CA 19-9[J].J Gastrointest Cancer,2016,25(05):90-92.
[4] 曹霞,王雅琴,杨娉婷,等.血清胸苷激酶1在26055例健康体检人群肿瘤风险筛查中的应用[J].中南大学学报:医学版,2014,24(10):1029-1034.
[5] 卞光荣,陈丽,王西珍,等.血清CA19-9、CA125和PET/CT显像联合检测对胰腺癌的诊断价值[J].中国卫生检验杂志,2015,25(22):3897-3898.
[6] 李学彦,郭晓钟,李宏宇,等.肿瘤标志物检测在胰腺癌诊断和预后评估中的价值研究[J].中国实用内科杂志,2014,32(05):499-503.
[7] MATTES M D,CARDINAL J S,JACOBSON G M.Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer[J].Radiat Oncol J,2016,34(2):156-159
[8] AL-SHAMSI H O,ALZAHRANI M,WOLFF R A.The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases[J].J Gastrointest Oncol,2016,7(3):45-51.
[9] 王琳.血清CA19-9、CEA联合检测诊断胰腺癌的临床价值[J].齐齐哈尔医学院学报,2013,34(18):2716-2719.
[10] NUMATA K,MORINAGA S,KATAYAMA Y,et al.Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine[J].Anticancer Res,2016,36(5):2467-2474.
[11] 罗国培,龙江,刘辰,等.血清癌抗原19-9水平对胰腺癌可切除性判断的临床意义[J].中华肝胆外科杂志,2012,18(6):436-438.
[12] 张铮森,陆新良.胰腺癌预后的分子生物学指标研究进展[J].肿瘤,2015,25(07):816-822.
[13] 周菊英,姚怡敏,俞志英,等.血清胸苷激酶1在恶性肿瘤诊断和疗效评估中的意义[J].江苏医药,2012,32(09):1055-1058.
[14] 张小红,朱丽萍,王如瑛.超声联合CA19-9在胰腺癌诊断中的临床价值[J].中国药物与临床,2013,13(3):337-339.
[15] DRANKA-BOJAROWSKA D,LEKSTAN A,OLAKOWSKI M et al.The assessment of serum concentration of adiponectin,leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis[J].J Physiol Pharmacol,2015,66(5):653-663.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录